ArticleMaterials today. Bio2025
A tailored nanocarrier DMON and CpGs synergistically drive the formulation of a highly immunogenic and long-acting vaccine against echinococcosis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Intelligent CpG nanoplatforms for targeted cancer immunotherapy and immune remodeling.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydatid disease (echinococcosis) is a zoonotic parasitic disease that seriously endangers human health and livestock production. To develop a safer, more effective vaccine with an exceptionally long-lasting immune response, we employed an 'all-in-one' strategy to construct a nanovaccine against echinococcosis. In this system, a dendritic mesoporous organosilica nanoparticle (DMON), Eg95 antigen, and two types of CpG potentiators (CpG ODN and pCpG) were integrated into a single nanoplatform. Compared to the commercial Quil-A-formulated vaccine, these two nanovaccines exhibited significant advantages in inducing early, robust, and long-lasting protective immune responses, especially in terms of IgG1 antibody responses and Th1 cytokine TNF-α secretion. Notably, the certain adjuvant combination (DMON + pCpG) formulated-vaccine Eg95N + pCpG@DMON conferred stronger adjuvanticity to the antigen than Quil-A during the late stage (42-84 days). Systematic evaluation demonstrated excellent biodegradability and biosafety of DMON and its-based vaccine. This research provides a strong foundation for upgrading vaccines against echinococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.